Magazine Article | March 7, 2018

What's Next For Seattle Genetics?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

It’s Wednesday, Jan. 10, 2018, and Clay Siegall, Ph.D., and I are engaged in small talk, recalling when we both worked at Bristol-Myers Squibb and were the beneficiaries of “Team Shares,” a companywide stock-option program initiated in 1994. We’re in San Francisco for the annual J.P. Morgan Healthcare Conference (JPM), and Siegall, president, CEO, and chairman of Seattle Genetics, has agreed to meet me for an interview in this quiet second-floor space at the Kimpton Sir Francis Drake Hotel.

Our casual conversation continues until the ding-ding-ding of a cable car bell from the street below bursts through the room’s cracked window, reminding me that our time is short, and that I’m not here to simply reminisce about the “good old days.” Siegall and his company have been in the spotlight lately, especially with rumors swirling that its lead compound, ADCETRIS, might become a blockbuster. I’m here to find out how the company got to this point — and probably more importantly — what the future holds.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: